Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Lung Cancer Specialty Channel

Lung Cancer
Specialty Channel
News
FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-Positive Solid Tumors
04/08/2024

Stephanie Holland 

Stephanie Holland 
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated...
04/08/2024
Oncology
News
Risk-Directed Thromboprophylaxis Reduced Thromboembolism and Mortality Among Patients With Gastrointestinal and Lung Cancer
10/16/2023

Allison Casey

Allison Casey
In a phase 3 clinical trial, thrombosis rates of patients with gastrointestinal and lung cancer with high-risk profiles were mitigated to those comparable to the rates of patients with low-risk profiles with a risk-directed primary...
In a phase 3 clinical trial, thrombosis rates of patients with gastrointestinal and lung cancer with high-risk profiles were mitigated to those comparable to the rates of patients with low-risk profiles with a risk-directed primary...
In a phase 3 clinical trial,...
10/16/2023
Oncology
Deborah Doroshow, MD, PhD
Videos
RET, NTRK, NRG1, and ROS1 Fusions as Targets in Lung Cancer
09/23/2023

Featuring Deborah Doroshow, MD, PhD 

Featuring Deborah Doroshow, MD, PhD  ...
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Deborah Doroshow, MD, PhD, discussed the importance of screening patients with lung cancer for RET, ROS1, NTRK, and NRG1 fusions.
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Deborah Doroshow, MD, PhD, discussed the importance of screening patients with lung cancer for RET, ROS1, NTRK, and NRG1 fusions.
At the Great Debates & Updates...
09/23/2023
Oncology
News
Amivantamab Added to Chemotherapy Improves PFS Among Patients With Non-Small Cell Lung Cancer With EGFR Mutation
07/20/2023
Allison Casey
According to Janssen Pharmaceutical Companies of Johnson & Johnson, the addition of amivantamab to chemotherapy improved the progression-free survival of patients with NSCLC with an EGFR exon 20 insertion mutation.
According to Janssen Pharmaceutical Companies of Johnson & Johnson, the addition of amivantamab to chemotherapy improved the progression-free survival of patients with NSCLC with an EGFR exon 20 insertion mutation.
According to Janssen...
07/20/2023
Oncology
News
Encorafenib Plus Binimetinib Exhibited Clinical Efficacy and Safety Among Patients With BRAFV600E-Mutant Metastatic NSCLC
07/10/2023

Stephanie Holland

Stephanie Holland
Data from a phase 2 trial show that encorafenib plus binimetinib exhibited meaningful clinical efficacy and safety in BRAFV600E-mutant metastatic NSCLC.
Data from a phase 2 trial show that encorafenib plus binimetinib exhibited meaningful clinical efficacy and safety in BRAFV600E-mutant metastatic NSCLC.
Data from a phase 2 trial show...
07/10/2023
Oncology
News
No Difference in Overall Survival Between Immunotherapy Treatment Lengths Among Patients With Advanced NSCLC
07/10/2023

Amber Denham

Amber Denham
Patients with non–small cell lung cancer who are progression-free on immunotherapy may be able to stop therapy at 2 years with no effect on overall survival.
Patients with non–small cell lung cancer who are progression-free on immunotherapy may be able to stop therapy at 2 years with no effect on overall survival.
Patients with non–small cell...
07/10/2023
Oncology
News
Low-Dose Spiral Computed Tomography Screening Aids in Reduction of Lung Cancer Mortality
02/22/2023

Derek Cowsert

Derek Cowsert
In a prospective study, one-off low-dose spiral computed tomography screening demonstrated accuracy in detecting positive nodules and efficacy in reducing lung cancer mortality.
In a prospective study, one-off low-dose spiral computed tomography screening demonstrated accuracy in detecting positive nodules and efficacy in reducing lung cancer mortality.
In a prospective study, one-off...
02/22/2023
Oncology
News
Optimal Surgery and Treatment Options for Stage 1 Lung Adenocarcinoma/Tumors Spread Through Air Spaces
02/22/2023

Derek Cowsert

Derek Cowsert
A study found no difference in survival outcomes between sublobar resection and lobectomy among patients stage 1 lung adenocarcinoma/tumors spread through air spaces.
A study found no difference in survival outcomes between sublobar resection and lobectomy among patients stage 1 lung adenocarcinoma/tumors spread through air spaces.
A study found no difference in...
02/22/2023
Oncology
News
High Tumor Mutational Burden Associated With Improved Progression-Free Survival Among Patients With NSCLC
02/16/2023

Derek Cowsert

Derek Cowsert
A study found high tumor mutational burden to be associated with improved local-regional control and progression-free survival among patients with non-small cell lung cancer treated with chemoradiation and durvalumab.
A study found high tumor mutational burden to be associated with improved local-regional control and progression-free survival among patients with non-small cell lung cancer treated with chemoradiation and durvalumab.
A study found high tumor...
02/16/2023
Oncology
News
Early Progression Patterns of Lung Squamous Cell Carcinoma on Computed Tomography Images
02/07/2023

Derek Cowsert

Derek Cowsert
Findings from a study reveal lung squamous cell carcinoma initiated with a variety of image patterns on computed tomography.
Findings from a study reveal lung squamous cell carcinoma initiated with a variety of image patterns on computed tomography.
Findings from a study reveal...
02/07/2023
Oncology
News
Impact of Age on Quality of Life After Immune Checkpoint Inhibitor Treatment for Patients With Lung Cancer
02/07/2023

Derek Cowsert

Derek Cowsert
A study found old age to be a significant risk factor for lower quality of life scores for patients with lung cancer who received immune checkpoint inhibitor treatment.
A study found old age to be a significant risk factor for lower quality of life scores for patients with lung cancer who received immune checkpoint inhibitor treatment.
A study found old age to be a...
02/07/2023
Oncology

Advertisement

News

News
FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-Positive Solid Tumors
04/08/2024

Stephanie Holland 

Stephanie Holland 
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated...
04/08/2024
Oncology
News
Risk-Directed Thromboprophylaxis Reduced Thromboembolism and Mortality Among Patients With Gastrointestinal and Lung Cancer
10/16/2023

Allison Casey

Allison Casey
In a phase 3 clinical trial, thrombosis rates of patients with gastrointestinal and lung cancer with high-risk profiles were mitigated to those comparable to the rates of patients with low-risk profiles with a risk-directed primary...
In a phase 3 clinical trial, thrombosis rates of patients with gastrointestinal and lung cancer with high-risk profiles were mitigated to those comparable to the rates of patients with low-risk profiles with a risk-directed primary...
In a phase 3 clinical trial,...
10/16/2023
Oncology
Deborah Doroshow, MD, PhD
Videos
RET, NTRK, NRG1, and ROS1 Fusions as Targets in Lung Cancer
09/23/2023

Featuring Deborah Doroshow, MD, PhD 

Featuring Deborah Doroshow, MD, PhD  ...
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Deborah Doroshow, MD, PhD, discussed the importance of screening patients with lung cancer for RET, ROS1, NTRK, and NRG1 fusions.
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Deborah Doroshow, MD, PhD, discussed the importance of screening patients with lung cancer for RET, ROS1, NTRK, and NRG1 fusions.
At the Great Debates & Updates...
09/23/2023
Oncology
News
Amivantamab Added to Chemotherapy Improves PFS Among Patients With Non-Small Cell Lung Cancer With EGFR Mutation
07/20/2023
Allison Casey
According to Janssen Pharmaceutical Companies of Johnson & Johnson, the addition of amivantamab to chemotherapy improved the progression-free survival of patients with NSCLC with an EGFR exon 20 insertion mutation.
According to Janssen Pharmaceutical Companies of Johnson & Johnson, the addition of amivantamab to chemotherapy improved the progression-free survival of patients with NSCLC with an EGFR exon 20 insertion mutation.
According to Janssen...
07/20/2023
Oncology
News
Encorafenib Plus Binimetinib Exhibited Clinical Efficacy and Safety Among Patients With BRAFV600E-Mutant Metastatic NSCLC
07/10/2023

Stephanie Holland

Stephanie Holland
Data from a phase 2 trial show that encorafenib plus binimetinib exhibited meaningful clinical efficacy and safety in BRAFV600E-mutant metastatic NSCLC.
Data from a phase 2 trial show that encorafenib plus binimetinib exhibited meaningful clinical efficacy and safety in BRAFV600E-mutant metastatic NSCLC.
Data from a phase 2 trial show...
07/10/2023
Oncology
News
No Difference in Overall Survival Between Immunotherapy Treatment Lengths Among Patients With Advanced NSCLC
07/10/2023

Amber Denham

Amber Denham
Patients with non–small cell lung cancer who are progression-free on immunotherapy may be able to stop therapy at 2 years with no effect on overall survival.
Patients with non–small cell lung cancer who are progression-free on immunotherapy may be able to stop therapy at 2 years with no effect on overall survival.
Patients with non–small cell...
07/10/2023
Oncology
News
Low-Dose Spiral Computed Tomography Screening Aids in Reduction of Lung Cancer Mortality
02/22/2023

Derek Cowsert

Derek Cowsert
In a prospective study, one-off low-dose spiral computed tomography screening demonstrated accuracy in detecting positive nodules and efficacy in reducing lung cancer mortality.
In a prospective study, one-off low-dose spiral computed tomography screening demonstrated accuracy in detecting positive nodules and efficacy in reducing lung cancer mortality.
In a prospective study, one-off...
02/22/2023
Oncology
News
Optimal Surgery and Treatment Options for Stage 1 Lung Adenocarcinoma/Tumors Spread Through Air Spaces
02/22/2023

Derek Cowsert

Derek Cowsert
A study found no difference in survival outcomes between sublobar resection and lobectomy among patients stage 1 lung adenocarcinoma/tumors spread through air spaces.
A study found no difference in survival outcomes between sublobar resection and lobectomy among patients stage 1 lung adenocarcinoma/tumors spread through air spaces.
A study found no difference in...
02/22/2023
Oncology
News
High Tumor Mutational Burden Associated With Improved Progression-Free Survival Among Patients With NSCLC
02/16/2023

Derek Cowsert

Derek Cowsert
A study found high tumor mutational burden to be associated with improved local-regional control and progression-free survival among patients with non-small cell lung cancer treated with chemoradiation and durvalumab.
A study found high tumor mutational burden to be associated with improved local-regional control and progression-free survival among patients with non-small cell lung cancer treated with chemoradiation and durvalumab.
A study found high tumor...
02/16/2023
Oncology
News
Early Progression Patterns of Lung Squamous Cell Carcinoma on Computed Tomography Images
02/07/2023

Derek Cowsert

Derek Cowsert
Findings from a study reveal lung squamous cell carcinoma initiated with a variety of image patterns on computed tomography.
Findings from a study reveal lung squamous cell carcinoma initiated with a variety of image patterns on computed tomography.
Findings from a study reveal...
02/07/2023
Oncology

Interactive Features

Quiz
Quiz: Treatment-Related Adverse Events in Patients with NSCLC Treated With Tiragolumab Plus Atezolizumab
09/08/2022
What did the phase 2 CITYSCAPE trial find to be the most common treatment-related adverse event in patients with non-small cell lung cancer treated with a combination of tiragolumab and atezolizumab?
What did the phase 2 CITYSCAPE trial find to be the most common treatment-related adverse event in patients with non-small cell lung cancer treated with a combination of tiragolumab and atezolizumab?
What did the phase 2 CITYSCAPE...
09/08/2022
Oncology
Quiz
Quiz: Agradasib-Related Adverse Events in Patients With KRAS-Mutated NSCLC
09/08/2022
According a phase 2 study, what percentage of patients with KRASG12C-mutated NSCLC experienced treatment-related adverse events when treated with adagrasib?
According a phase 2 study, what percentage of patients with KRASG12C-mutated NSCLC experienced treatment-related adverse events when treated with adagrasib?
According a phase 2 study, what...
09/08/2022
Oncology
elderly screening patient
Quiz
Novel MS-VMAT Technique for Whole Lung Irradiation
03/15/2022
At the 2022 ACRO Annual Meeting, experts revealed that a dosimetric advantage was observed with bone marrow sparing VMAT over the standard technique for whole lung irradiation.
At the 2022 ACRO Annual Meeting, experts revealed that a dosimetric advantage was observed with bone marrow sparing VMAT over the standard technique for whole lung irradiation.
At the 2022 ACRO Annual Meeting,...
03/15/2022
Oncology
Test Your Knowledge
Quiz: Is Lurbinectedin Beneficial for Patients with Pretreated SCLC and Mesothelioma?
12/09/2021
True or false: According to real-world data, lurbinectedin did not demonstrate clinical benefit for heavily pretreated patients with small cell lung cancer and mesothelioma.
True or false: According to real-world data, lurbinectedin did not demonstrate clinical benefit for heavily pretreated patients with small cell lung cancer and mesothelioma.
True or false: According to...
12/09/2021
Oncology
Quiz
Quiz: Dose Escalation in Esophageal Cancer
08/15/2021
True or false: According to experts who presented at the ACRO Annual Conference, dose escalation is achievable for patients with esophageal cancer.
True or false: According to experts who presented at the ACRO Annual Conference, dose escalation is achievable for patients with esophageal cancer.
True or false: According to...
08/15/2021
Oncology
Test Your Knowledge
Quiz: Pembrolizumab Plus CRT for Locally Advanced NSCLC
08/09/2021
True or false: Pembrolizumab in combination with concurrent chemoradiation therapy offered promising clinical activity in patients with locally advanced non-small cell lung cancer.
True or false: Pembrolizumab in combination with concurrent chemoradiation therapy offered promising clinical activity in patients with locally advanced non-small cell lung cancer.
True or false: Pembrolizumab in...
08/09/2021
Oncology
Test Your Knowledge
Quiz: Is Pralsetinib Beneficial for RET+ NSCLC?
08/06/2021
True or false: Oral pralsetinib has been shown to yield promising overall response rates in patients with RET+ NSCLC.
True or false: Oral pralsetinib has been shown to yield promising overall response rates in patients with RET+ NSCLC.
True or false: Oral pralsetinib...
08/06/2021
Oncology
Test Your Knowledge
Quiz: What Combo Therapy Yields Benefit in Patients with EGFR Mutated Advanced NSCLC?
08/03/2021
The combination of first-generation EGFR-TKIs and ______ achieves a satisfactory PFS, ORR, DCR, and well-tolerated toxicity in advanced NSCLC patients with EGFR mutations.
The combination of first-generation EGFR-TKIs and ______ achieves a satisfactory PFS, ORR, DCR, and well-tolerated toxicity in advanced NSCLC patients with EGFR mutations.
The combination of...
08/03/2021
Oncology
Test Your Knowledge
Quiz: Which treatment benefits patients with KRAS p.G12C-mutated non-small cell lung cancer?
07/06/2021
Which treatment showed efficacy and manageable safety in patients with previously treated KRAS p.G12C-mutated non-small cell lung cancer?
Which treatment showed efficacy and manageable safety in patients with previously treated KRAS p.G12C-mutated non-small cell lung cancer?
Which treatment showed efficacy...
07/06/2021
Oncology
Test Your Knowledge
Quiz: Which Treatment Received FDA Approval for ALK+ NSCLC?
03/23/2021
Which of the following treatments recently received FDA approval for ALK+ Non-Small Cell Lung Cancer?
Which of the following treatments recently received FDA approval for ALK+ Non-Small Cell Lung Cancer?
Which of the following...
03/23/2021
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-Positive Solid Tumors
04/08/2024

Stephanie Holland 

Stephanie Holland 
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.
The FDA granted accelerated...
04/08/2024
Oncology
News
Risk-Directed Thromboprophylaxis Reduced Thromboembolism and Mortality Among Patients With Gastrointestinal and Lung Cancer
10/16/2023

Allison Casey

Allison Casey
In a phase 3 clinical trial, thrombosis rates of patients with gastrointestinal and lung cancer with high-risk profiles were mitigated to those comparable to the rates of patients with low-risk profiles with a risk-directed primary...
In a phase 3 clinical trial, thrombosis rates of patients with gastrointestinal and lung cancer with high-risk profiles were mitigated to those comparable to the rates of patients with low-risk profiles with a risk-directed primary...
In a phase 3 clinical trial,...
10/16/2023
Oncology
News
Amivantamab Added to Chemotherapy Improves PFS Among Patients With Non-Small Cell Lung Cancer With EGFR Mutation
07/20/2023
Allison Casey
According to Janssen Pharmaceutical Companies of Johnson & Johnson, the addition of amivantamab to chemotherapy improved the progression-free survival of patients with NSCLC with an EGFR exon 20 insertion mutation.
According to Janssen Pharmaceutical Companies of Johnson & Johnson, the addition of amivantamab to chemotherapy improved the progression-free survival of patients with NSCLC with an EGFR exon 20 insertion mutation.
According to Janssen...
07/20/2023
Oncology
News
Encorafenib Plus Binimetinib Exhibited Clinical Efficacy and Safety Among Patients With BRAFV600E-Mutant Metastatic NSCLC
07/10/2023

Stephanie Holland

Stephanie Holland
Data from a phase 2 trial show that encorafenib plus binimetinib exhibited meaningful clinical efficacy and safety in BRAFV600E-mutant metastatic NSCLC.
Data from a phase 2 trial show that encorafenib plus binimetinib exhibited meaningful clinical efficacy and safety in BRAFV600E-mutant metastatic NSCLC.
Data from a phase 2 trial show...
07/10/2023
Oncology
News
No Difference in Overall Survival Between Immunotherapy Treatment Lengths Among Patients With Advanced NSCLC
07/10/2023

Amber Denham

Amber Denham
Patients with non–small cell lung cancer who are progression-free on immunotherapy may be able to stop therapy at 2 years with no effect on overall survival.
Patients with non–small cell lung cancer who are progression-free on immunotherapy may be able to stop therapy at 2 years with no effect on overall survival.
Patients with non–small cell...
07/10/2023
Oncology
News
Low-Dose Spiral Computed Tomography Screening Aids in Reduction of Lung Cancer Mortality
02/22/2023

Derek Cowsert

Derek Cowsert
In a prospective study, one-off low-dose spiral computed tomography screening demonstrated accuracy in detecting positive nodules and efficacy in reducing lung cancer mortality.
In a prospective study, one-off low-dose spiral computed tomography screening demonstrated accuracy in detecting positive nodules and efficacy in reducing lung cancer mortality.
In a prospective study, one-off...
02/22/2023
Oncology
News
Optimal Surgery and Treatment Options for Stage 1 Lung Adenocarcinoma/Tumors Spread Through Air Spaces
02/22/2023

Derek Cowsert

Derek Cowsert
A study found no difference in survival outcomes between sublobar resection and lobectomy among patients stage 1 lung adenocarcinoma/tumors spread through air spaces.
A study found no difference in survival outcomes between sublobar resection and lobectomy among patients stage 1 lung adenocarcinoma/tumors spread through air spaces.
A study found no difference in...
02/22/2023
Oncology
News
High Tumor Mutational Burden Associated With Improved Progression-Free Survival Among Patients With NSCLC
02/16/2023

Derek Cowsert

Derek Cowsert
A study found high tumor mutational burden to be associated with improved local-regional control and progression-free survival among patients with non-small cell lung cancer treated with chemoradiation and durvalumab.
A study found high tumor mutational burden to be associated with improved local-regional control and progression-free survival among patients with non-small cell lung cancer treated with chemoradiation and durvalumab.
A study found high tumor...
02/16/2023
Oncology
News
Early Progression Patterns of Lung Squamous Cell Carcinoma on Computed Tomography Images
02/07/2023

Derek Cowsert

Derek Cowsert
Findings from a study reveal lung squamous cell carcinoma initiated with a variety of image patterns on computed tomography.
Findings from a study reveal lung squamous cell carcinoma initiated with a variety of image patterns on computed tomography.
Findings from a study reveal...
02/07/2023
Oncology
News
Impact of Age on Quality of Life After Immune Checkpoint Inhibitor Treatment for Patients With Lung Cancer
02/07/2023

Derek Cowsert

Derek Cowsert
A study found old age to be a significant risk factor for lower quality of life scores for patients with lung cancer who received immune checkpoint inhibitor treatment.
A study found old age to be a significant risk factor for lower quality of life scores for patients with lung cancer who received immune checkpoint inhibitor treatment.
A study found old age to be a...
02/07/2023
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement